Tests DIAG723 in adults with hereditary hemorrhagic telangiectasia
Tests DIAG723, compared with placebo, for safety in adults with hereditary hemorrhagic telangiectasia.
Plain-language title generated from the registry record
Registry title: DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
Key facts
- Where
- Laval and Toronto, CanadaSee the 2 sites
- Phase
- Phase 1/2
Where in Canada
- LavalLaval, CanadaNot yet recruiting
- TorontoToronto, CanadaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Diagonal Therapeutics, Inc.
- Trial code
- NCT07623525
- Record updated
- 8 September 2026
- Original description
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT).Read full original descriptionShow less
A Phase 1/2, First-in-Human, Multicenter, Ascending Single-Dose and Multi-Dose Study to Assess the Safety of DIAG723, a Novel Bispecific ALK-1 and BMPRII Agonist Antibody in Adult Patients With Hereditary Hemorrhagic Telangiectasia (DIAMOND Trial)
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT).
The study consists of three parts:
Part A (dose escalation): Single ascending subcutaneous doses of DIAG723 are evaluated in sequential cohorts to assess safety, tolerability, and pharmacokinetics.
Part B (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT to assess safety and preliminary efficacy.
Part C (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT and concomitant pulmonary arterial hypertension to assess safety and exploratory clinical effects in this population.
Participants will be randomized within each study part to receive DIAG723 or placebo. The study includes dose escalation in Part A and dose expansion in Parts B and C.
Inclusion: Adult patients ≥18 years with a clinical or genetic diagnosis of HHT; Adequate hepatic and renal function; Part B: Epistaxis and anemia or transfusion/iron history; Part C: HHT with documented pre-capillary pulmonary arterial hypertension.
Exclusion: Use of anti-angiogenic drugs within 6 weeks; Active or recent systemic infection; Recent thromboembolic events; Pregnancy or lactation; Recent participation in another investigational study.